Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy
10.1371/journal.pone.0148901
Saved in:
Main Authors: | Wang X.J., Tang T., Farid M., Quek R., Tao M., Lim S.T., Wee H.L., Chan A. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
Public Library of Science (PLoS)
2018
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/142662 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Breakthrough febrile neutropenia and associated complications in non-Hodgkin's lymphoma patients receiving pegfilgrastim
by: Ng, J.H., et al.
Published: (2014) -
Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients
by: Chan, A., et al.
Published: (2014) -
The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
by: Thungthong P.
Published: (2023) -
CHOP and R-CHOP Therapeutic Responses in Non-HODGKIN Lymphoma Patients in Dr. Soetomo General Hospital Surabaya
by: Rina Syarifah Salma, et al.
Published: (2018) -
Fluoroquinolone Prophylaxis Against Febrile Neutropenia in Areas With High Fluoroquinolone Resistance-An Asian Perspective
by: Ng, E.S.T., et al.
Published: (2016)